Quantcast

Precision Therapeutics, Inc. Named to Pittsburgh Business Times 2010 Top 100

September 2, 2010

PITTSBURGH, Sept. 2 /PRNewswire/ — Precision Therapeutics ranked first place as an industry leader in the health care division and third place across all industries on the Pittsburgh Business Times Top 100 list, which identifies the area’s fastest-growing, privately held companies.

With a growth rate of 847% since 2007, Precision has become an industry leader in personalized cancer therapy by recently hiring 100 new employees and raising $35 million in venture capital to provide additional support for expanding the distribution of the Company’s core product, ChemoFx®.

“I believe this award belongs to each and every Precision employee. It is with great pride that I extend my congratulations and gratitude for their tremendous skills and efforts in helping us to achieve this prestigious honor,” says Sean McDonald, CEO of Precision Therapeutics.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients. Known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual’s cancer.

Precision’s state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient’s cancer offers an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. For more information, please visit www.precisiontherapeutics.com.

About ChemoFx®

Precision’s first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual’s malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.chemofx.com.

SOURCE Precision Therapeutics


Source: newswire



comments powered by Disqus